No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
661 |
4. Check minimum number of eventsNone |
661 |
5. Include endpointsNone |
661 |
6. Filter based on genotype QC (FinnGen only) |
661 |
Control definitions (FinnGen only)
- Control exclude
- F5_SLEEP
Extra metadata
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Disorder of the sleep-wake schedule
based on the number of shared cases.
Similar with more cases:
- Sleep disorders
- Behavioural syndromes associated with physiological disturbances and physical factors
- Sleep disorders (combined)
- Psychiatric diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 6901 | 3035 | 3847 |
| Only index persons | 5380 | 2449 | 2931 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.10 | 0.09 | 0.11 |
| Only index persons | 0.10 | 0.09 | 0.11 |
| Median age at first event (years) | |||
| Whole population | 17.72 | 18.07 | 17.36 |
| Only index persons | 23.48 | 23.54 | 23.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 661 | 358 | 303 |
| Unadjusted period prevalence (%) | 0.13 | 0.12 | 0.13 |
| Median age at first event (years) | 41.67 | 37.75 | 46.30 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 579
- Matched controls
- 5789
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G47.2
ICD-10 Finland
Disorders of the sleep-wake schedule
2785.7
323.0
285
*
F51.2
ICD-10 Finland
Nonorganic disorder of the sleep-wake schedule
555.7
294.0
269
9
G47.3
ICD-10 Finland
Sleep apnoea
5.9
70.2
242
627
N05AH04
ATC
quetiapine; oral
5.8
65.7
224
564
N06AX11
ATC
mirtazapine; oral
4.4
55.6
272
972
F51.0
ICD-10 Finland
Nonorganic insomnia
6.4
55.1
163
333
IAB13
NOMESCO Finland
Psychiatric sleep disorder consultation
519.5
49.1
48
*
G47.9
ICD-10 Finland
Sleep disorder, unspecified
15.2
37.6
63
46
N05CF01
ATC
zopiclone; oral
3.6
37.1
216
828
3074F
ICD-9 Finland
Special symptoms or syndromes not elsewhere classified, Specific disorders of sleep of nonorganic origin[UNIVALVERYTMIN HÄIRIÖ]
+∞
36.9
35
*
F32.9
ICD-10 Finland
Depressive episode, unspecified
4.1
33.7
152
464
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.3
33.1
137
385
IEY18
NOMESCO Finland
Psychiatric sleep coaching, individual
+∞
29.4
28
*
N06AX12
ATC
bupropion; oral
5.1
29.4
99
223
N06AX05
ATC
trazodone; oral
14.4
28.8
49
37
N05BA04
ATC
oxazepam; oral
3.2
28.0
183
736
N06AB10
ATC
escitalopram; oral
3.1
27.2
180
729
N06AX16
ATC
venlafaxine; oral
3.7
27.1
136
447
F51.9
ICD-10 Finland
Nonorganic sleep disorder, unspecified
15.8
26.9
44
30
N05AH03
ATC
olanzapine; systemic
5.6
25.9
79
158
N06AB04
ATC
citalopram; systemic
3.1
24.8
159
625
N03AX16
ATC
pregabalin; oral
3.1
24.5
160
634
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
12.8
23.7
42
35
G47.0
ICD-10 Finland
Disorders of initiating and maintaining sleep [insomnias]
13.8
23.3
40
31
N06AB03
ATC
fluoxetine; oral
3.6
23.1
115
371
R5140
NOMESCO Finland
Monitoring the use of the aid
4.3
23.1
93
249
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
7.0
23.0
58
90
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
6.5
22.8
61
103
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
4.3
22.4
88
230
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
8.5
21.7
48
61
F61.0
ICD-10 Finland
Mixed personality disorders
10.2
21.7
43
45
N03AX09
ATC
lamotrigine; oral
5.5
21.6
66
132
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
4.9
21.3
73
166
N05CF02
ATC
zolpidem; oral
3.2
20.9
127
472
R40.0
ICD-10 Finland
Somnolence
217.5
20.7
21
*
N06AB06
ATC
sertraline; oral
3.5
20.5
105
345
P06
ICPC
Sleep disturbance
3.6
19.4
95
301
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
3.4
19.3
102
343
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
8.1
19.0
43
57
N06BA04
ATC
methylphenidate; oral
5.7
18.7
55
105
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.4
18.4
98
331
F34.1
ICD-10 Finland
Dysthymia
6.0
18.3
51
91
R06.5
ICD-10 Finland
Mouth breathing
3.7
18.3
86
263
N05BA01
ATC
diazepam; systemic, rectal
3.4
18.2
96
322
N03AG01
ATC
valproic acid; systemic, rectal
5.0
17.3
57
124
IDY03
NOMESCO Finland
Systematic individual therapy, cognitive-behavioural
6.8
17.1
43
67
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
5.8
17.0
49
91
R53
ICD-10 Finland
Malaise and fatigue
2.6
16.9
140
629
N05AX12
ATC
aripiprazole; systemic
5.0
16.6
54
116
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
4.7
16.5
58
135
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
5.6
16.3
48
92
N03AE01
ATC
clonazepam; systemic
5.1
16.2
52
110
N06AX03
ATC
mianserin; oral
6.7
16.1
41
65
N06AX22
ATC
agomelatine; oral
8.4
16.0
35
44
P03
ICPC
Feeling depressed
2.9
16.0
107
421
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.9
16.0
69
196
N04BC05
ATC
pramipexole; oral
4.8
15.8
53
118
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
3.1
15.6
91
325
N06AB05
ATC
paroxetine; oral
4.4
15.4
57
140
F41.1
ICD-10 Finland
Generalized anxiety disorder
4.3
15.4
58
145
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
10.1
15.4
30
31
N05CD07
ATC
temazepam; oral
3.9
15.3
65
182
F90.0
ICD-10 Finland
Disturbance of activity and attention
4.4
15.2
56
137
N06AX21
ATC
duloxetine; oral
3.3
15.1
83
283
T36
ICD-10 Finland
Poisoning by systemic antibiotics
4.7
15.0
52
120
P76
ICPC
Depressive disorder
3.5
14.8
73
231
N06AX26
ATC
vortioxetine; oral
4.0
14.8
61
166
N05AA02
ATC
levomepromazine; systemic
5.7
14.2
41
77
N06AA09
ATC
amitriptyline; systemic
3.6
14.1
66
201
IBA04
NOMESCO Finland
Extensive initial psychiatric evaluation
7.0
13.9
34
51
IBB02
NOMESCO Finland
Psychiatric evaluation of working capacity and rehabilitation
20.7
13.9
20
10
N03AX12
ATC
gabapentin; oral
2.7
13.8
100
410
A02BC02
ATC
pantoprazole; systemic
2.0
13.6
326
2303
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.0
13.6
228
1403
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
6.1
13.4
36
62
C07AA05
ATC
propranolol; systemic
2.4
13.1
125
597
WX722
NOMESCO Finland
PEEP
4.7
13.0
44
99
N05AX08
ATC
risperidone; systemic
3.6
12.9
60
182
R03AC02
ATC
salbutamol; inhalant
1.9
12.6
314
2224
XG466
NOMESCO Finland
Sleep oxymetry
5.4
12.5
37
72
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
5.8
11.8
33
60
M79.6
ICD-10 Finland
Pain in limb
2.0
11.8
189
1129
IGY02
NOMESCO Finland
Psychiatric monitoring contact
4.8
11.6
38
83
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
4.7
11.6
39
88
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
11.3
155
867
N06AA12
ATC
doxepin; systemic
4.9
11.1
36
78
IGY99
NOMESCO Finland
Other psychiatric treatment contact
5.5
11.1
32
61
F29
ICD-10 Finland
Unspecified nonorganic psychosis
4.2
11.0
41
102
E66.01
ICD-10 Finland
Obesity due to excess calories
3.0
10.9
66
241
R06.0
ICD-10 Finland
Dyspnoea
2.2
10.8
130
684
R03BA05
ATC
fluticasone; inhalant
2.2
10.7
124
646
N05BE01
ATC
buspirone; oral
5.4
10.3
30
58
R52.9
ICD-10 Finland
Pain, unspecified
3.0
10.3
59
209
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
4.7
10.2
34
76
WX723
NOMESCO Finland
CPAP therapy
4.7
10.2
34
76
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
10.2
128
686
IBA03
NOMESCO Finland
Psychotherapy evaluation
8.7
10.1
21
25
P74
ICPC
Anxiety disorder/anxiety state
3.4
10.1
49
154
M79.7
ICD-10 Finland
Fibromyalgia
4.9
10.1
32
68
IBA01
NOMESCO Finland
Diagnostic and symptom-mapping evaluation
6.0
10.1
27
47
A06AC01
ATC
ispaghula (psylla seeds); oral
2.2
10.0
112
572
A02BC05
ATC
esomeprazole; systemic
1.8
10.0
202
1301
F33
ICD-10 Finland
Recurrent depressive disorder
6.1
9.9
26
44
F31.4
ICD-10 Finland
Bipolar affective disorder, current episode severe depression without psychotic symptoms
7.6
9.8
22
30
P99
ICPC
Psychological disorders other
4.7
9.7
32
71
G47.1
ICD-10 Finland
Disorders of excessive somnolence [hypersomnias]
55.9
9.7
11
*
F60.3
ICD-10 Finland
Emotionally unstable personality disorder
11.6
9.6
17
15
J45.9
ICD-10 Finland
Asthma, unspecified
2.2
9.5
106
538
R03DC03
ATC
montelukast; oral
2.2
9.5
104
526
F31.0
ICD-10 Finland
Bipolar affective disorder, current episode hypomanic
8.9
9.3
19
22
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.9
9.3
58
216
D11
ICPC
Diarrhoea
2.3
9.3
90
429
P29
ICPC
Psychological sympt/compl other
2.8
9.2
61
236
N05AF03
ATC
chlorprothixene; systemic
4.9
9.2
29
62
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.5
9.1
74
323
R51.80
ICD-10 Finland
Headache
2.2
9.1
105
540
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.7
9.1
61
239
IFA01
NOMESCO Finland
Psychiatric pharmacotherapy plan, not specified
5.6
9.0
25
46
F60.9
ICD-10 Finland
Personality disorder, unspecified
7.6
9.0
20
27
C03CA01
ATC
furosemide; systemic
2.2
8.9
100
511
L01
ICPC
Neck symptom/complaint
2.2
8.7
90
442
R01AD09
ATC
mometasone; nasal
1.7
8.6
256
1833
A04
ICPC
Weakness/tiredness general
2.2
8.6
91
452
N02AX02
ATC
tramadol; systemic, rectal
1.8
8.5
205
1379
F31.8
ICD-10 Finland
Other bipolar affective disorders
5.8
8.5
23
41
A02BC03
ATC
lansoprazole; oral
1.9
8.5
130
750
N05AB03
ATC
perphenazine; systemic, rectal
5.0
8.5
26
54
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.8
8.5
53
199
E66.00
ICD-10 Finland
Metabolic syndrome
3.5
8.4
38
114
F39
ICD-10 Finland
Unspecified mood [affective] disorder
5.4
8.4
24
46
Z29
ICPC
Social problem NOS
5.5
8.2
23
43
A06AD11
ATC
lactulose; oral
2.5
8.2
67
292
H03AA01
ATC
levothyroxine sodium; systemic
2.0
8.1
110
605
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
17.5
8.1
12
7
331
Kela drug reimbursment
Atomoxetine, dexamphetamine, guanfacine and lisdexamphetamine
9.1
8.1
16
18
F51
ICD-10 Finland
Nonorganic sleep disorders
3.9
8.1
32
86
UDQ12
NOMESCO Finland
Flexible laryngoscopy
3.5
8.0
36
108
F41.09
ICD-10 Finland
UNS Panic Syndrome
3.8
8.0
32
87
J31.0
ICD-10 Finland
Chronic rhinitis
2.6
7.9
55
221
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
5.0
7.8
24
50
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.3
7.8
75
355
SPAT1240
SPAT
Therapeutic discussion
2.1
7.8
90
462
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
7.8
204
1400
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
3.2
7.8
39
127
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
1.9
7.8
131
783
M25.5
ICD-10 Finland
Pain in joint
1.8
7.7
151
947
M79.1
ICD-10 Finland
Myalgia
2.2
7.7
79
385
L28
ICPC
Limited function/disability (L)
2.3
7.6
70
326
F41.8
ICD-10 Finland
Other specified anxiety disorders
3.6
7.6
33
96
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
1.7
7.6
193
1313
N05AB01
ATC
dixyrazine; systemic
10.2
7.6
14
14
L03
ICPC
Low back symptom/complaint
1.8
7.6
137
836
N06AG02
ATC
moclobemide; oral
3.6
7.5
32
92
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.5
7.5
60
258
Z03.2
ICD-10 Finland
Observation for suspected mental and behavioural disorders
5.2
7.5
22
44
ICB02
NOMESCO Finland
Psychiatric treatment plan, extended/prolonged
6.6
7.5
18
28
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.1
7.5
40
137
N06AA04
ATC
clomipramine; systemic
8.5
7.4
15
18
H02AB06
ATC
prednisolone; systemic
1.7
7.3
224
1600
N05AE04
ATC
ziprasidone; systemic
9.5
7.3
14
15
IER02
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, group
9.5
7.3
14
15
N05AN01
ATC
lithium; oral
4.9
7.2
22
46
N05BA06
ATC
lorazepam; systemic, sublingual
3.6
7.2
31
90
P01
ICPC
Feeling anxious/nervous/tense
2.0
7.1
97
533
N05BA12
ATC
alprazolam; oral
2.5
7.1
55
234
N02BE01
ATC
paracetamol; systemic, rectal
1.7
7.0
449
3874
DHB50
NOMESCO Finland
Turbinoplasty
3.9
7.0
27
72
F51.8
ICD-10 Finland
Other nonorganic sleep disorders
14.0
6.9
11
8
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.0
6.9
88
473
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.7
6.9
169
1130
E66.8
ICD-10 Finland
Other obesity
3.0
6.8
37
128
M79.0
ICD-10 Finland
Rheumatism, unspecified
4.6
6.8
22
49
H02AB07
ATC
prednisone; oral
2.2
6.8
67
323
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.8
6.8
140
888
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.6
6.8
47
188
L02
ICPC
Back symptom/complaint
2.3
6.8
61
280
F51.1
ICD-10 Finland
Nonorganic hypersomnia
40.5
6.8
8
*
IAB07
NOMESCO Finland
Consultation concerning a patient with self-harm intention
16.9
6.8
10
6
L29
ICPC
Musculoskeletal sympt/complt other
2.6
6.8
47
189
R52.2
ICD-10 Finland
Other chronic pain
4.0
6.8
25
64
SHA02
NOMESCO Finland
Correction of physiology of bite - basic therapy visit
2.6
6.7
48
197
M01AB05
ATC
diclofenac; systemic, rectal
1.6
6.6
324
2585
N06BA07
ATC
modafinil; oral
12.4
6.6
11
9
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
6.5
55
247
N06AA06
ATC
trimipramine; systemic
4.8
6.5
20
43
WX110
NOMESCO Finland
Local anesthesy
1.6
6.4
403
3408
K59.09
ICD-10 Finland
Constipation, unspecified
3.0
6.4
36
126
M03BC01
ATC
orphenadrine (citrate); systemic
1.8
6.4
121
746
F42.2
ICD-10 Finland
Mixed obsessional thoughts and acts
8.3
6.4
13
16
SHA01
NOMESCO Finland
Correction of physiology of bite - simple therapy visit
2.2
6.4
66
326
K57.3
ICD-10 Finland
Diverticular disease of large intestine without perforation or abscess
2.2
6.3
65
316
J34.2
ICD-10 Finland
Deviated nasal septum
2.8
6.3
38
141
K07.60
ICD-10 Finland
Snapping jaw
2.8
6.3
38
141
A28
ICPC
Limited function/disability NOS
2.3
6.3
58
269
N06BA12
ATC
lisdexamfetamine; oral
9.4
6.3
12
13
M54.9
ICD-10 Finland
Dorsalgia, unspecified
2.1
6.3
68
342
N03AX11
ATC
topiramate; oral
4.4
6.3
21
49
G47.8
ICD-10 Finland
Other sleep disorders
7.1
6.2
14
20
WX780
NOMESCO Finland
Remote monitoring CPAP
3.4
6.2
28
85
M54.5
ICD-10 Finland
Low back pain
1.6
6.2
170
1166
G47.4
ICD-10 Finland
Narcolepsy and cataplexy
27.0
6.2
8
*
SPAT1051
SPAT
Guidance regarding sleep disorders
5.4
6.2
17
32
R01AD58
ATC
fluticasone, combinations; inhalant, nasal
1.8
6.2
118
732
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.1
6.1
31
103
R06AE07
ATC
cetirizine; oral
1.6
6.1
242
1821
F32.1
ICD-10 Finland
Moderate depressive episode
2.6
6.1
43
174
K59.0
ICD-10 Finland
Constipation
3.3
6.1
29
92
R07.4
ICD-10 Finland
Chest pain, unspecified
1.8
6.1
122
765
G44.2
ICD-10 Finland
Tension-type headache
2.0
6.1
74
388
ICC01
NOMESCO Finland
Psychiatric treatment plan, transfer to psychiatric outpatient clinic
8.7
6.1
12
14
D01
ICPC
Abdominal pain/cramps general
2.0
6.0
74
391
R05
ICPC
Cough
1.7
6.0
126
801
C07AB07
ATC
bisoprolol; oral
1.6
6.0
180
1265
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
195
784
3.11
35.73
1.9
1.9
1.5
1.4
%
0.76
177
712
180
711
3.11
33.80
2.5
2.4
14.3
14.1
umol/l
0.15
167
654
312
1680
2.63
32.09
2.2
1.8
96.1
95.7
pmol/l
0.05
175
884
165
650
3.05
30.85
2.4
2.4
2.4
2.4
g/l
0.00
153
596
154
599
3.05
29.32
2.5
2.5
23.3
23.9
%
0.19
139
523
350
2051
2.50
29.31
6.5
7.7
1.2
1.2
mmol/l
2.07
322
1878
281
1488
2.55
29.29
2.7
3.2
2.4
2.4
mmol/l
0.16
257
1332
205
951
2.68
27.86
1.7
1.4
18.8
20.2
nmol/l
0.85
184
807
515
3708
2.77
26.50
7.7
7.1
80.4
81.1
u/l
0.13
493
3475
338
2038
2.35
25.39
2.8
2.4
72.5
73.3
nmol/l
0.20
315
1851
362
2248
2.35
25.38
7.0
7.8
1.2
1.2
mmol/l
2.45
309
1915
157
674
2.74
24.52
2.0
1.7
1068.6
1141.0
nmol/l
0.44
121
509
292
1734
2.23
21.81
3.6
3.4
27.3
32.1
u/l
1.91
277
1646
531
4035
2.62
21.75
5.0
3.7
14.5
14.6
pmol/l
0.38
491
3668
78
240
3.55
21.49
1.7
1.7
3.5
3.5
mg/l
0.03
72
167
125
519
2.74
20.55
2.4
2.2
406.9
373.0
nmol/l
0.87
114
486
301
1877
2.11
19.17
5.1
5.4
36.5
36.5
g/l
0.01
278
1754
495
3770
2.25
18.08
4.8
3.8
9.9
9.9
mm/h
0.01
471
3472
423
3054
2.07
17.46
9.7
8.9
4.1
4.0
e9/l
0.63
366
2657
163
825
2.30
17.30
1.8
1.7
47328669.8
19236638.1
pmol/l
0.24
131
707
366
2523
2.01
17.02
3.8
2.7
95.1
98.0
ug/l
0.14
339
2339
357
2475
1.96
15.95
5.9
6.4
12.0
13.8
umol/l
0.99
328
2331
578
4851
2.54
14.53
6.3
4.3
1.8
2.1
mu/l
0.59
540
4482
239
1496
1.94
13.98
2.9
2.6
53.7
57.6
u/l
0.85
219
1379
476
3729
1.99
13.90
4.1
3.1
44.7
41.6
u/l
0.39
457
3527
213
1287
1.97
13.79
2.2
2.1
260.7
273.8
u/l
0.05
194
1219
202
1203
1.98
13.61
2.9
2.1
2.8
2.9
mg/l
0.54
172
1032
570
4801
2.37
13.39
4.8
3.8
5.9
5.8
mmol/l
0.98
527
4416
605
5257
2.81
12.91
17.9
13.0
139.6
139.6
mmol/l
0.23
594
5097
535
4421
2.11
12.75
5.9
4.8
39.7
38.7
mmol/mol
0.60
497
4142
604
5272
2.72
12.23
18.1
13.1
3.9
4.0
mmol/l
0.52
591
5099
384
2879
1.80
11.99
5.5
5.3
6.7
6.5
mmol/l
0.78
358
2638
43
133
3.39
11.70
1.4
1.5
277.5
276.1
ug/g
0.01
26
74
224
1448
1.83
11.39
3.3
3.5
8.4
8.3
mmol/l
0.16
187
1235
144
826
1.95
10.50
2.7
2.5
134.1
120.5
ug/g
0.13
116
651
97
481
2.19
10.47
2.5
2.3
24.5
34.9
u/l
2.79
75
405
26
63
4.26
9.98
1.5
1.8
—
—
—
0
0
247
1703
1.72
9.74
4.1
3.2
—
—
—
0
0
220
1480
1.73
9.42
1.6
1.4
0.7
1.6
u/ml
1.94
51
376
128
730
1.93
9.41
3.6
4.5
0.8
0.8
mmol/l
0.05
112
694
624
5667
2.85
9.23
12.4
9.1
29.2
27.5
u/l
0.90
609
5477
418
3350
1.68
9.04
5.2
3.9
2055.0
738.6
e6/l
—
9
41
13
18
7.35
8.87
1.2
1.1
—
—
—
0
0
13
18
7.35
8.87
1.8
2.2
15.2
17.7
umol/l
0.32
13
18
603
5431
2.28
8.39
17.1
11.6
18.7
21.6
mg/l
1.68
482
4151
544
4736
1.85
8.23
14.4
10.3
91.2
90.7
ml/min/173m2
0.20
452
3765
113
645
1.91
8.23
6.4
7.7
1.1
1.1
mmol/l
0.37
105
607
177
1163
1.71
8.06
3.5
3.3
1.0
1.0
kg/l
0.14
26
164
120
705
1.86
7.98
2.7
2.6
2.4
2.4
mmol/l
0.35
108
621
67
319
2.22
7.96
5.1
3.4
4.6
4.7
pmol/l
0.41
55
280
34
117
3.01
7.81
4.8
4.6
37.8
37.7
umol/l
0.01
27
103
11
15
7.44
7.57
1.9
2.7
—
—
—
0
0
61
296
2.17
6.92
2.0
1.5
—
—
—
0
0
194
1354
1.61
6.84
4.1
3.1
0.3
0.3
e6/l
0.39
149
1013
13
24
5.51
6.79
2.3
5.6
43.4
169.1
umol/l
—
5
11
19
50
3.88
6.57
1.6
3.9
—
—
—
0
0
19
52
3.73
6.24
1.6
3.8
10.5
14.8
%
—
8
33
134
881
1.65
5.92
1.4
1.3
18.9
29.5
iu/ml
1.21
40
274
100
613
1.74
5.71
3.1
3.4
7.1
8.4
umol/l
0.30
83
518
72
399
1.90
5.70
7.2
7.6
1.3
1.2
mmol/l
0.04
54
286
556
5028
1.67
5.45
4.8
4.2
2.8
2.8
mmol/l
0.70
517
4669
59
311
1.99
5.41
4.2
5.0
84.0
73.6
ng/l
0.33
52
285
73
417
1.84
5.27
8.5
9.5
7.1
7.7
mmol/l
0.44
67
402
85
512
1.76
5.15
5.2
6.2
—
—
—
0
0
32
134
2.46
5.13
1.5
1.9
409.0
454.5
mg/l
0.33
32
128
313
2536
1.45
5.11
4.0
3.2
0.0
0.0
estimate
0.00
61
498
76
444
1.80
5.10
1.3
1.2
88.9
156.6
iu/ml
1.14
17
182
146
1016
1.56
5.04
3.5
3.4
1289.8
986.7
ng/l
0.18
111
834
215
1625
1.48
5.03
4.6
3.1
30.7
43.5
ng/l
0.44
136
952
43
207
2.15
5.02
2.1
1.7
—
—
—
0
0
59
325
1.90
4.77
4.9
6.7
24.6
23.7
mmol/l
1.39
51
307
124
842
1.58
4.75
1.3
1.3
17.5
9.1
u/ml
0.44
42
338
312
2570
1.41
4.44
4.1
3.3
0.0
0.0
estimate
0.00
61
490
113
764
1.58
4.39
3.9
2.9
3.7
2.5
e6/l
0.36
62
417
79
488
1.70
4.39
3.0
2.3
12.1
13.3
nmol/l
0.62
71
441
16
50
3.25
4.36
1.2
1.8
32.9
32.5
pg
0.10
16
50
8
271
0.29
4.35
1.3
1.6
—
—
—
0
0
308
2548
1.39
4.20
5.5
4.5
0.0
0.0
estimate
0.50
64
520
5
215
0.23
4.18
1.6
1.4
—
—
—
0
0
66
393
1.75
4.18
1.0
1.0
—
—
—
0
0
542
4958
1.52
4.11
4.4
3.8
1.5
1.4
mmol/l
0.06
505
4623
161
1190
1.47
4.11
4.5
4.2
9.7
11.2
mg/mmol
0.20
102
772
29
130
2.29
4.05
1.6
1.9
12.2
8.1
e6/l
0.16
23
96
27
118
2.34
3.99
2.3
2.6
—
—
—
0
0
543
4978
1.51
3.99
4.5
3.8
4.5
4.7
mmol/l
1.80
510
4668
35
171
2.11
3.98
1.3
1.5
268.9
231.2
u/ml
0.36
20
90
36
178
2.08
3.97
1.4
1.5
—
—
—
0
0
82
530
1.62
3.84
4.1
3.9
30.7
31.6
%
0.32
61
353
569
5291
1.55
3.67
17.2
12.5
40.6
40.6
%
0.03
426
4230
9
16
5.69
3.67
2.9
2.2
—
—
—
0
0
43
237
1.87
3.52
2.0
1.7
—
—
—
0
0
642
6186
2.39
3.47
25.2
17.1
137.1
137.1
g/l
0.02
636
6106
155
1174
1.42
3.42
2.9
2.8
354.4
6170.0
umol/l
4.18
132
1029
112
798
1.49
3.41
3.5
2.8
1.0
0.9
e6/l
0.14
61
449
32
591
0.52
3.36
1.8
1.6
—
—
—
0
0
18
71
2.58
3.32
1.5
1.3
—
—
—
0
0
16
62
2.62
3.06
1.1
1.4
—
—
—
0
0
67
438
1.59
3.02
3.9
10.6
1.8
0.9
mmol/l
0.99
56
350
13
46
2.86
2.93
1.0
1.1
—
—
—
0
0
70
466
1.56
2.93
3.0
4.8
228.0
249.0
u/l
0.89
65
448
46
275
1.72
2.92
2.5
1.9
—
—
—
0
0
13
47
2.80
2.83
1.0
1.1
—
—
—
0
0
97
699
1.45
2.79
2.1
1.9
—
—
—
0
0
161
1268
1.36
2.77
1.8
1.7
1.6
1.4
mmol/l
1.03
137
1086
173
1378
1.35
2.77
4.2
3.5
0.0
0.0
estimate
1.08
59
507
77
531
1.51
2.76
3.3
7.9
103.5
104.3
mmol/l
0.68
71
523
515
4770
1.36
2.75
4.1
3.5
1.4
1.3
mmol/l
2.59
475
4455
145
1125
1.37
2.74
2.2
2.1
1.0
1.2
mg/l
0.35
102
830
13
48
2.74
2.73
1.3
1.1
—
—
—
0
0
9
233
0.38
2.72
1.3
1.7
—
—
—
0
0
22
105
2.13
2.71
4.9
2.7
4.9
4.8
kpa
0.25
22
105
53
337
1.62
2.69
6.2
3.9
1.2
1.2
mmol/l
0.02
43
294
72
493
1.52
2.67
4.6
6.1
2.1
1.6
mmol/l
0.64
59
382
32
543
0.57
2.55
1.4
1.5
—
—
—
0
0
155
1234
1.33
2.47
3.0
2.4
—
—
—
0
0
67
460
1.51
2.46
2.8
2.8
0.2
0.2
g/l
0.16
62
430
20
96
2.12
2.45
1.8
1.4
—
—
—
0
0
20
96
2.12
2.45
1.8
1.4
—
—
—
0
0
36
212
1.74
2.44
4.6
13.9
25.5
24.4
mmol/l
0.90
31
201
509
4736
1.33
2.41
20.3
14.4
13.5
13.5
%
0.23
501
4648
143
1129
1.34
2.41
2.8
2.2
—
—
—
0
0
24
125
1.95
2.38
1.1
1.9
3.2
3.1
g/l
0.20
16
103
32
184
1.78
2.36
1.0
1.1
1.0
8.7
u/ml
—
7
26
42
262
1.64
2.33
1.5
1.7
5.0
8.0
u/l
2.53
29
214
107
812
1.38
2.32
3.4
3.1
46.3
689.3
ng/l
2.42
72
544
235
2002
1.27
2.23
3.9
3.2
—
—
—
0
0
39
242
1.65
2.21
1.3
1.4
—
—
—
0
0
64
448
1.47
2.16
4.9
2.9
—
—
—
0
0
20
102
1.99
2.12
3.1
3.6
52.5
55.2
%
0.38
20
102
10
37
2.73
2.11
2.1
2.1
—
—
—
0
0
23
124
1.89
2.09
1.5
1.5
—
—
—
0
0
5
10
5.03
2.07
1.4
1.5
—
—
—
0
0
7
20
3.53
2.06
1.1
1.3
—
—
—
0
0
24
134
1.82
1.98
1.1
1.9
4.3
3.8
g/l
0.74
16
101
24
134
1.82
1.98
1.1
1.9
8.0
7.3
g/l
0.65
16
108
24
134
1.82
1.98
1.1
1.9
—
—
—
0
0
19
99
1.95
1.92
2.3
3.3
4.1
3.9
e9/l
0.14
19
99
33
206
1.63
1.86
3.4
2.2
45.0
39.2
u/l
0.98
28
189
23
130
1.80
1.84
2.7
2.1
13.1
11.5
mg/l
0.45
23
122
5
12
4.19
1.82
1.2
1.1
87.3
79.5
ug/l
—
5
12
5
12
4.19
1.82
1.8
2.2
2.3
1.5
nmol/l
—
5
12
28
169
1.69
1.80
2.3
1.9
—
—
—
0
0
19
102
1.89
1.78
1.1
1.0
2.6
2.2
u/ml
0.11
12
43
21
117
1.82
1.76
1.7
1.5
—
—
—
0
0
6
18
3.35
1.75
1.0
1.3
—
—
—
0
0
12
55
2.20
1.68
1.5
3.1
4.0
3.4
nmol/l
0.25
12
55
14
69
2.05
1.65
1.3
1.3
—
—
—
0
0
65
483
1.38
1.63
2.0
1.8
—
—
—
0
0
28
176
1.62
1.57
1.3
1.1
—
—
—
0
0
28
176
1.62
1.57
1.3
1.1
—
—
—
0
0
18
100
1.82
1.54
1.6
1.2
—
0.9
—
0
6
8
33
2.44
1.54
1.1
1.1
—
—
—
0
0
8
33
2.44
1.54
1.3
1.3
—
—
—
0
0
39
267
1.49
1.52
2.0
1.3
—
—
—
0
0
19
108
1.78
1.52
1.1
1.3
—
—
—
0
0
43
303
1.45
1.46
1.4
1.6
21.8
19.5
iu/l
0.14
29
253
65
494
1.35
1.44
2.0
1.8
—
—
—
0
0
12
59
2.05
1.44
1.0
1.1
—
—
—
0
0
13
66
1.99
1.44
1.3
1.4
0.6
0.6
nmol/l
0.04
13
60
9
39
2.33
1.43
1.0
1.2
—
92.2
—
0
6
18
104
1.75
1.38
1.7
1.2
—
—
—
0
0
19
112
1.72
1.36
1.6
1.3
—
—
—
0
0
10
47
2.15
1.34
1.4
1.3
0.0
0.1
u/ml
—
5
16
25
160
1.58
1.33
2.2
1.8
—
—
—
0
0
155
1331
1.22
1.31
3.9
4.3
2.3
2.1
ug/l
0.06
138
1205
24
364
0.65
1.30
1.4
1.4
—
—
—
0
0
5
18
2.79
1.28
1.4
3.4
—
—
—
0
0
5
18
2.79
1.28
1.4
3.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
18
107
1.70
1.27
2.8
6.2
0.5
0.3
u/ml
—
10
54
13
70
1.87
1.24
1.2
1.1
—
—
—
0
0
6
25
2.41
1.24
1.2
1.4
—
—
—
0
0
264
2394
1.17
1.19
3.9
4.1
—
—
—
0
0
16
94
1.72
1.18
1.7
1.5
11.8
20.4
u/l
0.66
11
79
5
20
2.51
1.15
1.2
1.3
—
—
—
0
0
22
143
1.56
1.13
1.5
1.6
126.4
102.6
u/ml
—
8
23
8
41
1.96
1.09
1.3
1.2
—
—
—
0
0
8
41
1.96
1.09
1.3
1.2
—
—
—
0
0
139
1203
1.20
1.08
2.4
2.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
34
2.07
1.03
1.1
1.1
—
—
—
0
0
88
733
1.23
1.01
2.3
2.1
—
—
—
0
0
9
49
1.85
0.99
1.1
1.1
—
—
—
0
0
43
329
1.33
0.97
2.4
2.4
71.0
72.4
ml/min/173m2
0.10
22
133
18
117
1.55
0.94
4.4
1.7
0.9
0.8
nmol/l
0.24
18
101
6
27
2.23
0.93
1.3
1.1
56.2
103.2
u/l
—
6
20
6
27
2.23
0.93
1.3
1.1
5.8
34.4
u/l
—
6
20
21
302
0.69
0.92
1.4
1.5
—
—
—
0
0
72
595
1.24
0.90
2.0
1.9
—
—
—
0
0
11
63
1.76
0.90
1.0
1.3
—
—
—
0
0
11
63
1.76
0.90
1.0
1.3
—
—
—
0
0
11
63
1.76
0.90
1.0
1.3
—
—
—
0
0
6
29
2.08
0.89
2.2
1.3
—
—
—
0
0
8
42
1.92
0.89
1.3
1.2
—
—
—
0
0
8
42
1.92
0.89
1.3
1.2
—
—
—
0
0
8
42
1.92
0.89
1.3
1.2
—
—
—
0
0
8
42
1.92
0.89
1.4
2.8
13.3
23.1
ug/l
—
8
42
13
79
1.66
0.88
2.0
1.5
—
—
—
0
0
10
56
1.80
0.88
1.0
1.1
—
—
—
0
0
6
30
2.01
0.87
2.3
2.0
308.7
838.0
u/ml
—
6
30
11
64
1.73
0.86
1.1
1.3
—
—
—
0
0
11
64
1.73
0.86
1.0
1.3
—
—
—
0
0
11
64
1.73
0.86
1.1
1.3
—
—
—
0
0
6
31
1.94
0.84
2.7
2.3
571.8
582.6
ml
—
6
16
10
57
1.77
0.84
2.2
1.5
—
—
—
0
0
11
65
1.70
0.82
1.0
1.4
—
—
—
0
0
6
32
1.88
0.82
1.5
1.8
—
—
—
0
0
14
89
1.59
0.81
1.6
1.4
—
—
—
0
0
13
82
1.60
0.78
1.6
1.6
—
—
—
0
0
6
34
1.77
0.76
3.7
1.5
—
—
—
0
0
10
59
1.71
0.76
2.3
1.5
—
—
—
0
0
36
280
1.30
0.76
2.5
2.6
88.5
162.0
ng/l
1.53
30
248
9
53
1.71
0.75
1.0
1.1
—
—
—
0
0
9
54
1.68
0.74
1.2
1.1
—
—
—
0
0
5
24
2.09
0.74
3.2
1.6
—
—
—
0
0
15
100
1.51
0.73
1.8
1.3
—
—
—
0
0
7
40
1.76
0.71
1.9
1.6
—
—
—
0
0
7
40
1.76
0.71
1.1
1.5
—
—
—
0
0
10
61
1.65
0.69
1.0
1.1
—
—
—
0
0
5
28
1.79
0.66
1.2
1.1
118.6
176.9
iu/ml
—
5
28
5
28
1.79
0.66
1.0
1.0
—
—
—
0
0
5
29
1.73
0.64
1.2
1.0
—
—
—
0
0
22
291
0.75
0.64
1.5
2.0
—
—
—
0
0
49
409
1.21
0.60
2.2
2.3
4944.6
3015.1
u/l
0.18
12
165
0
22
0.00
0.59
0.0
1.8
—
9.1
—
0
16
21
158
1.34
0.58
1.8
2.3
—
—
—
0
0
21
273
0.76
0.55
1.3
1.4
—
—
—
0
0
21
272
0.76
0.54
1.3
1.4
—
—
—
0
0
21
272
0.76
0.54
1.3
1.4
—
—
—
0
0
21
272
0.76
0.54
1.3
1.4
—
—
—
0
0
13
91
1.44
0.53
3.7
2.8
17.1
16.3
%
—
6
48
13
92
1.42
0.51
2.3
7.2
—
2224.6
—
0
13
7
45
1.56
0.49
2.3
1.2
—
—
—
0
0
22
172
1.29
0.48
2.1
2.2
1.7
1.4
g/l
0.73
17
145
7
46
1.53
0.48
1.1
1.1
—
—
—
0
0
22
173
1.28
0.47
3.7
4.5
3.4
3.5
g/l
0.10
22
166
86
773
1.13
0.46
2.6
2.7
0.6
0.7
ug/l
0.71
55
467
22
174
1.27
0.45
1.2
1.2
—
—
—
0
0
16
121
1.33
0.44
1.5
2.0
—
—
—
0
0
10
69
1.46
0.44
2.2
1.5
—
—
—
0
0
22
175
1.27
0.44
1.5
1.3
—
—
—
0
0
5
31
1.62
0.43
2.4
3.1
2.6
2.4
mmol/l
—
5
23
5
32
1.57
0.42
3.8
3.2
—
—
—
0
0
115
1059
1.10
0.41
3.3
3.8
21.3
21.4
%
0.03
45
452
0
15
0.00
0.41
0.0
1.3
—
303.1
—
0
9
8
60
1.34
0.40
3.1
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
8.8
—
0
18
9
66
1.37
0.38
1.3
1.7
—
—
—
0
0
14
108
1.30
0.35
1.9
2.5
134.9
128.8
g/l
—
9
80
6
45
1.34
0.34
1.0
1.6
—
—
—
0
0
16
197
0.81
0.31
1.1
1.2
6.2
1.9
u/ml
—
7
96
27
232
1.17
0.29
14.0
10.1
9.0
9.2
kpa
0.29
27
221
20
170
1.18
0.24
1.6
1.6
0.3
0.3
iu/ml
—
8
33
11
87
1.27
0.24
2.7
1.8
—
—
—
0
0
19
161
1.19
0.24
2.4
7.7
1.8
1.5
%
0.50
19
146
5
41
1.22
0.22
2.8
1.6
0.7
1.0
g/l
—
5
41
0
10
0.00
0.21
0.0
5.9
—
—
—
0
0
0
10
0.00
0.21
0.0
5.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
14
117
1.20
0.20
2.4
1.8
—
—
—
0
0
11
91
1.21
0.17
2.6
3.1
17.4
62.7
u/ml
0.46
11
83
156
1507
1.05
0.17
1.8
1.7
—
—
—
0
0
90
944
0.95
0.17
1.5
1.5
—
—
—
0
0
8
70
1.14
0.16
3.0
1.5
—
—
—
0
0
21
187
1.13
0.16
1.3
1.4
—
—
—
0
0
13
111
1.17
0.16
1.1
1.1
—
—
—
0
0
35
322
1.09
0.16
2.8
2.4
2.5
6.6
ug/l
4.61
26
290
9
81
1.11
0.15
1.0
1.1
—
—
—
0
0
15
171
0.87
0.15
1.4
1.5
—
—
—
0
0
42
393
1.07
0.13
1.4
1.3
—
—
—
0
0
12
104
1.16
0.12
1.9
4.0
40.6
30.4
mg/l
—
6
80
12
104
1.16
0.12
1.8
4.0
56.3
108.7
mg/l
—
6
79
10
86
1.17
0.11
1.2
1.1
—
—
—
0
0
5
44
1.14
0.10
1.0
2.4
—
—
—
0
0
5
62
0.80
0.08
1.2
1.6
—
—
—
0
0
13
117
1.11
0.08
2.5
1.7
—
—
—
0
0
10
88
1.14
0.08
1.5
1.2
10.8
5.5
u/ml
—
5
33
21
195
1.08
0.08
2.3
4.2
25.6
25.1
mmol/l
0.50
21
187
9
100
0.90
0.06
1.6
1.3
—
—
—
0
0
14
148
0.94
0.02
1.5
1.2
—
—
—
0
0
436
4372
0.99
0.02
3.8
3.6
—
—
—
0
0
11
105
1.05
0.00
1.3
1.1
—
—
—
0
0
28
277
1.01
0.00
1.3
1.4
166.3
262.7
miu/ml
—
9
140
13
129
1.01
0.00
1.5
1.8
—
—
—
0
0
35
351
1.00
0.00
2.7
4.5
3.5
19.3
ug/l
0.71
30
287
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
344.2
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
5
51
0.98
0.00
1.6
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
0.5
—
0
6
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
9.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
238.0
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint F5_SLEEPWAKE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_SLEEPWAKE | 2.192 [1.67, 2.88] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.03 |
During the follow-up period (1.1.1998 — 31.12.2019), 157 out of 2225 females with F5_SLEEPWAKE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_SLEEPWAKE | 2.046 [1.64, 2.55] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 288 out of 2839 males with F5_SLEEPWAKE died.
Mortality risk
Mortality risk for people of age
years, who have F5_SLEEPWAKE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.236% | 0.3% |
| 5 | 1.1% | 2.454% |
| 10 | 2.53% | 6.216% |
| 15 | 4.99% | 11.799% |
| 20 | 8.937% | 19.409% |
Relationships between endpoints
↥Index endpoint: F5_SLEEPWAKE – Disorder of the sleep-wake schedule
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data